Enabling Technologies to Accelerate Development of Oral Biodevices (R41/R42, R43/R44 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites applications that propose transformative engineering solutions to technical challenges associated with new development, substantial optimization of existing technologies and clinical translation of intraoral biodevices. Proposed technologies are expected to advance development of oral biodevices to clinical use, including but not limited to: precision medicine-based detection, diagnosis and treatment of oral and overall health conditions, and measurement of patient functional status and clinical outcome assessment. Areas of interest in this FOA include engineering approaches that allow integration of electronic, physical, and biological systems essential to the development of functional biodevices that are safe and effective for detection, diagnosis and treatment of oral and systemic disease. Products of this research will be proof-of-concept prototype biodevices, dedicated biosensors, associated core technologies and integrated approaches that enable development of safe and effective intra-oral biodevices intended for specific clinical applications. To streamline the development of oral biodevices that advance precision medicine-based approaches in clinical practice, this FOA encourages interdisciplinary collaborations across engineering, multifunctional sensors, pharmacology, chemistry, medicine, and dentistry, as well as between academia and industry.

Companion FOA: PA-19-076

SBIR/STTR Due Dates: Sep. 5, Jan. 5, Apr. 5

PA-19-075 Expiration Date January 06, 2022

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

Funding Type





Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Clinical Science
Medical - Translational

External Deadline

January 5, 2021